Pediatric follicular lymphomas involve interactions in MAPK and G-protein protein receptor signaling pathways, according to new research.
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Some distinct prognostic factors are observed for SOX11-negative compared with SOX11-positive mantle cell lymphoma.
While the cure rate of children with Burkitt lymphoma is approximately 90% in higher-income countries, only 20%–70% of children with these diseases are cured in lower- or middle-income countries.
A case report describing the diagnosis of anaplastic large cell lymphoma (ALCL) in a woman who underwent cosmetic placement of bilateral, textured silicone gluteal implants was published online in Aesthetic Surgery Journal. 1 The US Food and Drug Administration (FDA) recently issued an update regarding the number of reported cases of breast implant-associated ALCL (BIA-ALCL), a rare form of…
Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Patients with newly-diagnosed DLBCL receiving R-CHOP at or near full-dose intensity have improved overall survival, according to study authors.
A study of the use of precision medicine-based “radiomic” features to evaluate risk of refractory disease in early-stage Hodgkin lymphoma showed promising results.
Given the high likelihood of comorbidities and poor performance status in older patients with PCNSL, alternative treatment approaches are needed for this population of patients.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
Adults in the UK with R/R DLBCL and their health care providers now have the option of considering treatment with tisagenlecleucel, a CAR-T cell therapy.
Spliced events in NOTCH genes may facilitate risk stratification for patients with certain subtypes of DLBCL.
Initiation of a phase 1 clinical trial of ALLO-501, an allogeneic CAR-T candidate, in patients with NHL is planned for early 2019.
Detection of specific mutations in genes encoding for PD-L1 and PD-L2 may help predict which patients with lymphoma will benefit from immune checkpoint inhibitor therapy.
The leading cause of death for patients with follicular lymphoma was the disease itself, despite gains in survival due to rituximab treatment.
In the ZUMA-1 trial, axicabtagene ciloleucel showed durable responses and no new safety concerns in patients with relapsed or refractory large B-cell lymphoma.
Nivolumab monotherapy for R/R DLBCL failed to confer improved objective response rates, but did produce durable responses in 3 individuals.
Patients younger than 65 with double expressor diffuse large B-cell lymphoma had better outcomes with dose-adjusted EPOCH plus rituximab than R-CHOP.
Cellular examination of follicular lymphoma reveals malignant B-cell types, coexpression of T-cell immune checkpoints.